RizzaRA, GerichJE, HammondMW, et al.: Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med, 1980; 303:1313–1318.
2.
The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med, 2008; 359:1464–1476.
3.
FosterNC, MillerKM, TamborlaneWV, et al.: Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care, 2016; 39:e81–e82.
4.
TanenbaumML, HanesSJ, MillerKM, et al.: Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care, 2017; 40:181–187.
5.
Medtronic, Insulet, Tandem; Close Concerns estimates. Adam Brown, 2017.
6.
GargSK, WeinzimerSA, TamborlaneWV, et al.: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
7.
BergenstalRM, GargS, WeinzimerSA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
8.
BaileyTS, ChangA, ChristiansenA: Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol, 2015; 9:209–214.
9.
MissoML, EgbertsKJ, PageM, et al.: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev, 2010;CD005103. DOI: 10.1002/14651858.CD005103.pub2.
10.
TanenbergRJ, WelshJB: Patient behaviors associated with optimum glycemic outcomes with sensor augmented pump therapy: insights from the STAR-3 study. Endocr Pract, 2015; 21:41–45.
11.
MillerKM, FosterNC, BeckRW, et al.: Current state of type 1 diabetes in the U.S.: updated data from the T1D Exchange Clinic Registry. Diabetes Care, 2015; 38:971–978.
12.
HeiseT, Stender-PetersenK, HövelmannU, et al.: Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet, 2016; doi: 10.1007/s40262-016-0473-5.
